专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130203625A1 SUV420H1 AND SUV420H2 AS TARGET GENES FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： SUV420H1和SUV420H2作为癌症治疗和诊断的靶基因
公开(公告)号：US20130203625A1
公开(公告)日：2013-08-08
申请号：US13817812
申请日：2011-08-18
申请人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
发明人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
IPC分类号： G01N33/50 , C12Q1/68 , C12Q1/48 , G01N33/68
CPC分类号： G01N33/5011 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12Q1/48 , C12Q1/6897 , C12Y201/01043 , G01N33/57407 , G01N33/6872 , G01N2500/04
摘要： The present invention relates to the roles played by the SUV420H1 and SUV420H2 genes in carcinogenesis and features a method for treating or preventing cancer by administering a double-stranded molecule against the SUV420H1 or SUV420H2 gene or a composition or vector containing such a double-stranded molecule. The present invention also features methods and kits for detecting or diagnosing cancer in a subject, including detecting an expression level of the SUV420H1 or SUV420H2 gene. The present invention further features methods and kits for assessing or determining the prognosis of a subject with cancer, including detecting the expression level of an SUV420H2 gene. Also, disclosed are methods of screening for candidate substances for treating or preventing cancer or inhibiting cancer cell growth, using as an index their effect on the expression or activity of SUV420H1 or SUV420H2.
摘要翻译：本发明涉及SUV420H1和SUV420H2基因在癌发生中的作用，其特征在于通过对SUV420H1或SUV420H2基因施用双链分子或含有这种双链分子的组合物或载体来治疗或预防癌症的方法。本发明还特征在于检测或诊断受试者的癌症的方法和试剂盒，包括检测SUV420H1或SUV420H2基因的表达水平。本发明还涉及用于评估或确定患有癌症的受试者的预后的方法和试剂盒，包括检测SUV420H2基因的表达水平。此外，公开了使用作为SUV420H1或SUV420H2的表达或活性的指标作为指标来筛选用于治疗或预防癌症或抑制癌细胞生长的候选物质的方法。

2. 发明申请

US20140094387A1 SUV39H2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： SUV39H2作为癌症治疗和诊断的靶基因
公开(公告)号：US20140094387A1
公开(公告)日：2014-04-03
申请号：US14123403
申请日：2012-05-31
申请人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
发明人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
IPC分类号： C12Q1/68 , C12Q1/48
CPC分类号： C12Q1/6886 , C12N15/1137 , C12N2310/14 , C12Q1/48 , C12Q2600/136 , C12Q2600/158 , C12Y201/01043 , G01N33/5011 , G01N33/57407 , G01N33/57411 , G01N33/57423 , G01N33/57434 , G01N2500/04
摘要： Objective methods for detecting or diagnosing cancer, or determining a predisposition for developing cancer, particularly lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor, are described herein. In one embodiment, the diagnostic method involves determining an expression level of the SUV39H2 gene. The present invention further provides methods of screening for candidate substances useful in the treatment and/or prevention of an SUV39H2-associated cancer, such as lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor. The present invention further provides methods of inhibiting the cell growth and thereby treating or alleviating symptoms of an SUV39H2 associated cancer. The present invention also features double-stranded molecules against the SUV39H2 gene and vectors encoding thereof as well as compositions containing such components and their utility in connection with the treatment and prevention of an SUV39H2-associated cancer.
摘要翻译：本文描述了用于检测或诊断癌症或确定发展癌症，特别是肺癌，子宫颈癌，膀胱癌，食管癌，骨肉瘤，前列腺癌和软组织肿瘤的倾向的客观方法。在一个实施方案中，诊断方法包括确定SUV39H2基因的表达水平。本发明还提供了筛选用于治疗和/或预防SUV39H2相关癌症（例如肺癌，子宫颈癌，膀胱癌，食管癌，骨肉瘤，前列腺癌和软组织肿瘤）的候选物质的方法。本发明进一步提供抑制细胞生长，从而治疗或减轻SUV39H2相关癌症症状的方法。本发明还具有针对SUV39H2基因的双链分子及其编码载体以及含有这些组分的组合物及其与治疗和预防SUV39H2相关癌症有关的用途。

3. 发明申请

US20120045766A1 JARID1B FOR TARGET GENE OF CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： JARID1B针对目标癌基因治疗和诊断
公开(公告)号：US20120045766A1
公开(公告)日：2012-02-23
申请号：US13202742
申请日：2010-01-27
申请人： Yusuke Nakamura , Ryuji Hamamoto , Takuya Tsunoda
发明人： Yusuke Nakamura , Ryuji Hamamoto , Takuya Tsunoda
IPC分类号： C12Q1/68 , C12N15/63 , C40B30/04 , A61P35/02 , C07H21/00 , A61K31/713 , A61P35/00 , G01N33/574 , A61K31/7088
CPC分类号： A61K31/713 , C12N15/113 , C12N2310/14 , C12Q1/48 , C12Q1/6886 , C12Q2600/136 , C12Q2600/154 , G01N33/574 , G01N2333/91011 , G01N2500/00
摘要： The present invention relates to the roles played by the JARID1B genes in cancers and features a method for treating cancers by administering a composition comprising a double-stranded molecule against the JARID1B genes or a vector encoding them. The present invention also features methods for diagnosing cancers by detecting the expression of JARID1B. To that end, JARID1B serves as a serological biomarker for cancers. Also, disclosed are methods of identifying candidate agents for treating or preventing cancer or inhibiting cancer cell growth, using the expression of JARID1B in the cancer cells or the cell proliferation resulted from expression of JARID1B as an index.
摘要翻译：本发明涉及JARID1B基因在癌症中的作用，其特征在于通过对JARID1B基因或编码它们的载体施用包含双链分子的组合物来治疗癌症的方法。本发明还具有通过检测JARID1B的表达来诊断癌症的方法。为此，JARID1B作为癌症的血清学生物标志物。还公开了使用JARID1B在癌细胞中的表达或由JARID1B表达作为指标导致的细胞增殖来鉴定用于治疗或预防癌症或抑制癌细胞生长的候选药剂的方法。

4. 发明申请

US20140308678A1 SMYD2 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： SMYD2作为癌症治疗和诊断的靶基因
公开(公告)号：US20140308678A1
公开(公告)日：2014-10-16
申请号：US14354813
申请日：2012-06-29
申请人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
发明人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
IPC分类号： G01N33/574
CPC分类号： G01N33/57484 , C12Q1/689 , C12Q2600/158 , G01N33/57407
摘要： The present invention arises from the discovery that the SMYD2 gene is both specifically over-expressed in cancer and involved in cancer cell survival. The present invention features methods for detecting or diagnosing the presence of or predisposition for developing cancer, using the SMYD2 gene as a diagnostic marker. The present invention further provides methods of screening for therapeutic substances useful in either or both of the treatment and prevention of cancer.
摘要翻译：本发明的起因于SMYD2基因在癌症中特异性过度表达并涉及癌细胞存活的发现。本发明的特征在于使用SMYD2基因作为诊断标记来检测或诊断发展中的癌症的存在或倾向的方法。本发明还提供筛选用于治疗和预防癌症的治疗物质的方法。

5. 发明申请

US20130137748A1 WHSC1 AND WHSC1L1 FOR TARGET GENES OF CANCER THERAPY AND DIAGNOSIS 审中-公开
标题翻译： WHSC1和WHSC1L1用于靶向治疗癌症和诊断基因
公开(公告)号：US20130137748A1
公开(公告)日：2013-05-30
申请号：US13576917
申请日：2011-02-02
申请人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
发明人： Ryuji Hamamoto , Yusuke Nakamura , Takuya Tsunoda
IPC分类号： C12N15/113 , C12Q1/02 , G01N33/53
CPC分类号： C12N15/1137 , A61K31/713 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/53
摘要： Objective methods for diagnosing a predisposition to developing cancer, for example, bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma, are described herein. In one embodiment, the diagnostic method involves determining an expression level of a WHSC1 or WHSC1L1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of WHSC1 or WHSC1L1 associated disease, such as a cancer, e.g., bladder cancer, breast cancer, cholangiocellular carcinoma, CML, esophageal cancer, HCC, NSCLC, SCLC, osteosarcoma, pancreatic cancer, prostate cancer, renal cell carcinoma, soft tissue tumor and lymphoma. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of WHSC1 or WHSC1L1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions including them. Also, disclosed are methods of identifying substances for treating or/and preventing lung cancer, using as an index their effect on expression of a WHSC1 or WHSC1L1 gene, or a biological activity of a WHSC1 or WHSC1L1 polypeptide.
摘要翻译：用于诊断发展中癌症的倾向的客观方法，例如膀胱癌，乳腺癌，胆管细胞癌，CML，食管癌，HCC，NSCLC，SCLC，骨肉瘤，胰腺癌，前列腺癌，肾细胞癌，软组织肿瘤和淋巴瘤，在此描述。在一个实施方案中，诊断方法包括确定WHSC1或WHSC1L1基因的表达水平。本发明还提供筛选用于治疗WHSC1或WHSC1L1相关疾病的治疗剂的方法，例如癌症，例如膀胱癌，乳腺癌，胆管细胞癌，CML，食管癌，HCC，NSCLC，SCLC，骨肉瘤，胰腺癌，前列腺癌，肾细胞癌，软组织肿瘤和淋巴瘤。本发明还提供抑制细胞生长和治疗或减轻WHSC1或WHSC1L1相关疾病症状的方法。本发明还包括产物，包括双链分子和编码它们的载体以及包括它们的组合物。此外，公开了用于鉴定用于治疗或/和预防肺癌的物质的方法，以其对WHSC1或WHSC1L1基因表达的影响或WHSC1或WHSC1L1多肽的生物活性的指标。

6. 发明授权

US08354223B2 Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3 有权
标题翻译：鉴定SMYD3调节VEGFR1甲基化的药物的方法
公开(公告)号：US08354223B2
公开(公告)日：2013-01-15
申请号：US12664378
申请日：2008-06-13
申请人： Yusuke Nakamura , Yoichi Furukawa , Ryuji Hamamoto , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yoichi Furukawa , Ryuji Hamamoto , Shuichi Nakatsuru
IPC分类号： C12Q1/00
CPC分类号： C12Q1/48 , C12N9/1007 , G01N33/57415 , G01N33/57419 , G01N33/57438 , G01N33/57446 , G01N2333/71 , G01N2333/91011 , G01N2500/02
摘要： The present invention relates to methods for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of VEGFR1 by SMYD3. The invention further provides methods and pharmaceutical compositions for treating and preventing colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.
摘要翻译：本发明涉及确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更具体地涉及SMYD3对VEGFR1甲基化的调节剂的方法。本发明还提供了使用所鉴定的调节剂治疗和预防结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法和药物组合物。

7. 发明授权

US07968281B2 Methods of modulating SMYD3 for treatment of cancer 有权
标题翻译：调节SMYD3治疗癌症的方法
公开(公告)号：US07968281B2
公开(公告)日：2011-06-28
申请号：US11912860
申请日：2006-06-23
申请人： Yusuke Nakamura , Yoichi Furukawa , Ryuji Hamamoto , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yoichi Furukawa , Ryuji Hamamoto , Shuichi Nakatsuru
IPC分类号： C12Q1/00 , G01N33/53
CPC分类号： G01N33/5011 , C12Q1/48 , C12Y201/01043 , G01N33/57407 , G01N2333/4736 , G01N2333/91011 , G01N2500/02
摘要： The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.
摘要翻译：本发明的特征在于确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更特别是用于通过SMYD3进行视网膜母细胞瘤甲基化的调节剂。本发明还提供了使用所鉴定的调节剂预防或治疗结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法或药物组合物。 SMYD3（别名ZNFN3A1）的N-末端截短形式具有较高的甲基化活性。 Lys 824是SMYD3的RB1蛋白上优选的甲基化位点。

8. 发明授权

US08512944B2 PRMT1 for target genes of cancer therapy and diagnosis 有权
标题翻译： PRMT1用于癌症治疗和诊断的靶基因
公开(公告)号：US08512944B2
公开(公告)日：2013-08-20
申请号：US13060672
申请日：2009-08-25
申请人： Yusuke Nakamura , Ryuji Hamamoto , Akira Togashi
发明人： Yusuke Nakamura , Ryuji Hamamoto , Akira Togashi
IPC分类号： C12Q1/00
CPC分类号： C12N15/1137 , C12N2310/14 , C12Q1/6886 , C12Q2600/136 , C12Q2600/154 , C12Q2600/158 , C12Y201/01125 , G01N33/57407 , G01N33/57484 , G01N2500/10
摘要： Objective methods for diagnosing a predisposition to developing cancer, particularly bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer, are described herein. In one embodiment, the diagnostic method involves determining an expression level of PRMT1 gene. The present invention further provides methods of screening for therapeutic agents useful in the treatment of PRMT1 associated disease, such as a cancer, e.g. bladder cancer, gastric cancer, colorectal cancer, breast cancer, esophageal cancer, lung cancer, lymphoma, pancreatic cancer and testicular cancer. The present invention further provides methods of inhibiting the cell growth and treating or alleviating symptoms of PRMT1 associated diseases. The present invention also features products, including double-stranded molecules and vectors encoding thereof as well as to compositions comprising them.
摘要翻译：本文描述了用于诊断发展中的癌症，特别是膀胱癌，胃癌，结肠直肠癌，乳腺癌，食管癌，肺癌，淋巴瘤，胰腺癌和睾丸癌的易感性的客观方法。在一个实施方案中，诊断方法包括确定PRMT1基因的表达水平。本发明还提供筛选用于治疗PRMT1相关疾病例如癌症的治疗剂的方法，例如癌症。膀胱癌，胃癌，结肠直肠癌，乳腺癌，食管癌，肺癌，淋巴瘤，胰腺癌和睾丸癌。本发明还提供了抑制细胞生长和治疗或减轻PRMT1相关疾病症状的方法。本发明还涉及包括双链分子和编码它们的载体以及包含它们的组合物的产品。

9. 发明申请

US20090191181A1 METHODS OF MODULATING SMYD3 FOR TREATMENT OF CANCER 有权
标题翻译：调节SMYD3治疗癌症的方法
公开(公告)号：US20090191181A1
公开(公告)日：2009-07-30
申请号：US11912860
申请日：2006-06-23
申请人： Yusuke Nakamura , Yoichi Furukawa , Ryuji Hamamoto , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yoichi Furukawa , Ryuji Hamamoto , Shuichi Nakatsuru
IPC分类号： A61K39/395 , C12Q1/68 , A61P35/00
CPC分类号： G01N33/5011 , C12Q1/48 , C12Y201/01043 , G01N33/57407 , G01N2333/4736 , G01N2333/91011 , G01N2500/02
摘要： The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified. N-terminal truncated forms of SMYD3 (alias ZNFN3A1) have higher methylating activity. Lys 824 is a preferred methylation site on the RB1 protein for SMYD3.
摘要翻译：本发明的特征在于确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更特别是用于通过SMYD3进行视网膜母细胞瘤甲基化的调节剂。本发明还提供了使用所鉴定的调节剂预防或治疗结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法或药物组合物。 SMYD3（别名ZNFN3A1）的N-末端截短形式具有较高的甲基化活性。 Lys 824是SMYD3的RB1蛋白上优选的甲基化位点。

10. 发明申请

US20140134637A1 METHODS OF MODULATING SMYD3 FOR TREATMENT OF CANCER 审中-公开
标题翻译：调节SMYD3治疗癌症的方法
公开(公告)号：US20140134637A1
公开(公告)日：2014-05-15
申请号：US13092770
申请日：2011-04-22
申请人： Yusuke Nakamura , Yoichi Furukawa , Ryuji Hamamoto , Shuichi Nakatsuru
发明人： Yusuke Nakamura , Yoichi Furukawa , Ryuji Hamamoto , Shuichi Nakatsuru
IPC分类号： G01N33/50
CPC分类号： G01N33/5011 , C12Q1/48 , C12Y201/01043 , G01N33/57407 , G01N2333/4736 , G01N2333/91011 , G01N2500/02
摘要： The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.
摘要翻译：本发明的特征在于确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更特别是用于通过SMYD3进行视网膜母细胞瘤甲基化的调节剂。本发明还提供了使用所鉴定的调节剂预防或治疗结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法或药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式